-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio's ANKTIVA Plus BCG Meets Primary Endpoint in Bladder Cancer Trial

PUBT·11/09/2026 11:31:22
Listen to the news
ImmunityBio's ANKTIVA Plus BCG Meets Primary Endpoint in Bladder Cancer Trial
  • ImmunityBio announced that ANKTIVA combined with BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 bladder cancer trial.
  • The combination significantly improved efficacy versus BCG alone in BCG-naïve patients with high-grade non-muscle invasive bladder cancer involving carcinoma in situ.
  • Common adverse events were consistent with BCG alone. No treatment-related deaths were reported.
  • Additional study details will be presented at an upcoming medical congress.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109448906) on November 09, 2026, and is solely responsible for the information contained therein.